Identification of Novel Natural Products as Effective and Broad-Spectrum Anti-Zika Virus Inhibitors

Zika virus (ZIKV) infection during pregnancy leads to severe congenital Zika syndrome, which includes microcephaly and other neurological malformations. No therapeutic agents have, so far, been approved for the treatment of ZIKV infection in humans; as such, there is a need for a continuous effort to develop effective and safe antiviral drugs to treat ZIKV-caused diseases. After screening a natural product library, we have herein identified four natural products with anti-ZIKV activity in Vero E6 cells, including gossypol, curcumin, digitonin, and conessine. Except for curcumin, the other three natural products have not been reported before to have anti-ZIKV activity. Among them, gossypol exhibited the strongest inhibitory activity against almost all 10 ZIKV strains tested, including six recent epidemic human strains. The mechanistic study indicated that gossypol could neutralize ZIKV infection by targeting the envelope protein domain III (EDIII) of ZIKV. In contrast, the other natural products inhibited ZIKV infection by targeting the host cell or cell-associated entry and replication stages of ZIKV. A combination of gossypol with any of the three natural products identified in this study, as well as with bortezomib, a previously reported anti-ZIKV compound, exhibited significant combinatorial inhibitory effects against three ZIKV human strains tested. Importantly, gossypol also demonstrated marked potency against all four serotypes of dengue virus (DENV) human strains in vitro. Taken together, this study indicates the potential for further development of these natural products, particularly gossypol, as the lead compound or broad-spectrum inhibitors against ZIKV and other flaviviruses, such as DENV.

[1]  Fang Li,et al.  Rational Design of Zika Virus Subunit Vaccine with Enhanced Efficacy , 2019, Journal of Virology.

[2]  S. Khurana,et al.  Differential human antibody repertoires following Zika infection and the implications for serodiagnostics and disease outcome , 2019, Nature Communications.

[3]  S. Crovella,et al.  ZIKA virus entry mechanisms in human cells. , 2019, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[4]  L. Du,et al.  Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain , 2019, Viruses.

[5]  D. Kessler,et al.  Transfusion-Transmitted Zika Virus Infection in Pregnant Mice Leads to Broad Tissue Tropism With Severe Placental Damage and Fetal Demise , 2019, Front. Microbiol..

[6]  Lu Lu,et al.  Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD , 2019, Viruses.

[7]  K. Meng,et al.  Triterpenoids manipulate a broad range of virus-host fusion via wrapping the HR2 domain prevalent in viral envelopes , 2018, Science Advances.

[8]  Jenifer B. Kaplan,et al.  Inhibition of Flaviviruses by Targeting a Conserved Pocket on the Viral Envelope Protein. , 2018, Cell chemical biology.

[9]  N. Gray,et al.  Discovery of Immunologically Inspired Small Molecules That Target the Viral Envelope Protein. , 2018, ACS infectious diseases.

[10]  Yufei Wang,et al.  A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV , 2018, Journal of Virology.

[11]  Marcia C. Castro,et al.  Implications of Zika virus and congenital Zika syndrome for the number of live births in Brazil , 2018, Proceedings of the National Academy of Sciences.

[12]  H. Hotta,et al.  Time-of-addition and Temperature-shift Assays to Determine Particular Step(s) in the Viral Life Cycle that is Blocked by Antiviral Substance(s). , 2018, Bio-protocol.

[13]  D. Fremont,et al.  Critical neutralizing fragment of Zika virus EDIII elicits cross-neutralization and protection against divergent Zika viruses , 2018, Emerging Microbes & Infections.

[14]  C. Zorrilla,et al.  Zika Virus Infection in Pregnancy: Maternal, Fetal, and Neonatal Considerations , 2017, The Journal of infectious diseases.

[15]  T. Noda,et al.  Broad-spectrum antiviral agents: secreted phospholipase A2 targets viral envelope lipid bilayers derived from the endoplasmic reticulum membrane , 2017, Scientific Reports.

[16]  J. Sejvar,et al.  Zika virus disease-associated Guillain-Barré syndrome—Barranquilla, Colombia 2015–2016 , 2017, Journal of the Neurological Sciences.

[17]  G. Screaton,et al.  The immunopathology of dengue and Zika virus infections. , 2017, Current opinion in immunology.

[18]  A. Nath,et al.  Therapeutic Approaches for Zika Virus Infection of the Nervous System , 2017, Neurotherapeutics.

[19]  B. Duncan,et al.  Infection-related microcephaly after the 2015 and 2016 Zika virus outbreaks in Brazil: a surveillance-based analysis , 2017, The Lancet.

[20]  K. Yuen,et al.  A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses , 2017, Nature Communications.

[21]  Susan A. Jones,et al.  Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction , 2017, Cell Research.

[22]  D. Dimitrov,et al.  Anti-HIV antibody and drug combinations exhibit synergistic activity against drug-resistant HIV-1 strains. , 2017, The Journal of infection.

[23]  M. Vignuzzi,et al.  Curcumin inhibits Zika and chikungunya virus infection by inhibiting cell binding , 2017, Antiviral research.

[24]  C. Rice,et al.  Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico , 2017, Cell.

[25]  Daniel Lucey,et al.  Congenital Zika Syndrome in 2017. , 2017, JAMA.

[26]  Ping Liu,et al.  25‐Hydroxycholesterol Protects Host against Zika Virus Infection and Its Associated Microcephaly in a Mouse Model , 2017, Immunity.

[27]  S. Perlman,et al.  Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines , 2016, Nature Communications.

[28]  N. Low,et al.  Zika Virus Infection as a Cause of Congenital Brain Abnormalities and Guillain–Barré Syndrome: Systematic Review , 2016, bioRxiv.

[29]  Xuping Xie,et al.  Adenosine Analog NITD008 Is a Potent Inhibitor of Zika Virus , 2016, Open forum infectious diseases.

[30]  M. Beltramello,et al.  Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection , 2016, Science.

[31]  C. Nelson,et al.  Structural Basis of Zika Virus-Specific Antibody Protection , 2016, Cell.

[32]  Nikos Vasilakis,et al.  A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection. , 2016, Cell host & microbe.

[33]  Simon Cauchemez,et al.  Association between Zika virus and microcephaly in French Polynesia, 2013–15: a retrospective study , 2016, The Lancet.

[34]  R. DeBiasi,et al.  Zika Virus Infection with Prolonged Maternal Viremia and Fetal Brain Abnormalities , 2016 .

[35]  M. Diamond,et al.  Zika Virus: New Clinical Syndromes and Its Emergence in the Western Hemisphere , 2016, Journal of Virology.

[36]  A. Act,et al.  Zika Virus Infection in Pregnant Women in Rio de Janeiro - Preliminary Report. , 2016 .

[37]  K. Kelly,et al.  Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma , 2014, Pharmaceuticals.

[38]  Yufei Wang,et al.  Discovery of pentacyclic triterpenoids as potential entry inhibitors of influenza viruses. , 2014, Journal of medicinal chemistry.

[39]  Leonardo Padilla-S,et al.  Inhibitory effects of curcumin on dengue virus type 2-infected cells in vitro , 2013, Archives of Virology.

[40]  V. Dua,et al.  Anti-malarial property of steroidal alkaloid conessine isolated from the bark of Holarrhena antidysenterica , 2013, Malaria Journal.

[41]  F. Lang,et al.  Gossypol-induced suicidal erythrocyte death. , 2012, Toxicology.

[42]  Hong Lu,et al.  A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains , 2012, Retrovirology.

[43]  R. Ray,et al.  Identification of a Small-Molecule Entry Inhibitor for Filoviruses , 2011, Journal of Virology.

[44]  Rosanna W. Peeling,et al.  Dengue: a continuing global threat , 2010, Nature Reviews Microbiology.

[45]  G. Kuno,et al.  Full-length sequencing and genomic characterization of Bagaza, Kedougou, and Zika viruses , 2007, Archives of Virology.

[46]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[47]  K. Dodou.  Investigations on gossypol: past and present developments , 2005, Expert opinion on investigational drugs.

[48]  A. Debnath,et al.  N-Substituted Pyrrole Derivatives as Novel Human Immunodeficiency Virus Type 1 Entry Inhibitors That Interfere with the gp41 Six-Helix Bundle Formation and Block Virus Fusion , 2004, Antimicrobial Agents and Chemotherapy.

[49]  P. Kovacic.  Mechanism of drug and toxic actions of gossypol: focus on reactive oxygen species and electron transfer. , 2003, Current medicinal chemistry.

[50]  R. Kellner,et al.  Specific release of membrane-bound annexin II and cortical cytoskeletal elements by sequestration of membrane cholesterol. , 1997, Molecular biology of the cell.

[51]  W. Jongen,et al.  Glycoalkaloids selectively permeabilize cholesterol containing biomembranes. , 1996, Biochimica et biophysica acta.

[52]  G. Dawson,et al.  Differential solubilization of lipids along with membrane proteins by different classes of detergents. , 1995, Chemistry and physics of lipids.

[53]  S. Young,et al.  Synthesis and anti-HIV activity of 1,1'-dideoxygossypol and related compounds. , 1995, Journal of medicinal chemistry.

[54]  M. G. Low,et al.  Streptolysin-O induces release of glycosylphosphatidylinositol-anchored alkaline phosphatase from ROS cells by vesiculation independently of phospholipase action. , 1995, The Biochemical journal.

[55]  A. Esparís-Ogando,et al.  Permeabilization of MDCK cells with cholesterol binding agents: dependence on substratum and confluency. , 1994, The American journal of physiology.

[56]  R. Schinazi,et al.  Selective inhibition of human immunodeficiency virus type 1 replication by the (-) but not the (+) enantiomer of gossypol , 1989, Antimicrobial Agents and Chemotherapy.

[57]  P. Dorsett,et al.  Antiviral Activity of Gossypol and Apogossypol , 1975 .

[58]  P. Dorsett,et al.  Letter: Antiviral activity of gossypol and apogossypol. , 1975, Journal of pharmaceutical sciences.

[59]  Goriunova Lv,et al.  Study of antiviral effect of gossypol on chick embryo model , 1969 .

[60]  S. A. Vichkanova,et al.  [Study of antiviral effect of gossypol on chick embryo model]. , 1969, Farmakologiia i toksikologiia.

[61]  G. Dick,et al.  Zika virus. I. Isolations and serological specificity. , 1952, Transactions of the Royal Society of Tropical Medicine and Hygiene.